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Antibody to carbonic anhydrase II, an enzyme abundantly present in biliary epithelium, has been proposed as a diagnostic marker for antimitochondrial antibody-negative PBC. In this study we determine its prevalence and clinical significance in a large series of patients with antimitochondrial antibody-positive and -negative PBC. Reactivity to carbonic anhydrase II was sought by Western immunoblotting in sera from 215 consecutive patients with PBC (26 antimitochondrial antibody-negative), 13 with autoimmune hepatitis, 25 with primary Sjögren's syndrome (pSS), 12 with systemic sclerosis, 19 with systemic lupus erythematosus and 73 healthy subjects. The prevalence of antibody to carbonic anhydrase II (titre 1:100) in PBC was 8%. No specific reactivity to carbonic anhydrase II was found in antimitochondrial antibody-negative PBC (7% versus 8% in antimitochondrial antibody-positive PBC). Ascites (P = 0.006) and Sjögren's syndrome (SS) (P = 0.022) in PBC were significantly associated with presence of the antibody. In patients with SS associated with PBC, the prevalence (19%) was similar to that observed in pSS (16%). At a serum dilution of 1:40, the prevalence of positive sera in PBC rose to 27% but disease specificity was reduced. Our findings in a large population of PBC patients rule out a relation between presence of antibody to carbonic anhydrase II and lack of antimitochondrial antibody. The higher prevalence of ascites found in positive patients warrants further evaluation.     INTRODUCTIONA proportion of patients with clinical, biochemical and histological features typical of PBC are negative for antimitochondrial antibodies (AMA) [ 1 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b1#b1​)]. It is debated whether these patients are affected by a separate clinical entity [ 2 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b2#b2​), 3 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b3#b3​)], or they simply represent a variant of PBC [ 4 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b4#b4​) (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b5#b5​)–6 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b6#b6​)]. The search for distinct serological abnormalities is being actively pursued for diagnostic and classification purposes and may provide additional insights into the disease process [ 7 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b7#b7​), 8 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b8#b8​)]. In agreement with recent observations of ours [ 9 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b9#b9​)] and other authors [ 10 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b10#b10​)], as well as with recent updates on this issue [ 7 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b7#b7​), 8 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b8#b8​)], the term AMA−PBC will be used in the present study. The term 'autoimmune cholangitis' will be used to indicate the subgroup of AMA−patients who have positive antinuclear (ANA) or anti-smooth muscle (SMA) antibodies [ 2 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b2#b2​), 3 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b3#b3​)]. Antibody to carbonic anhydrase II (anti-CA II), as determined by Western blotting, has been recently reported to confer on AMA−PBC a distinctive pattern of immunoreactivity [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​)], although discordant findings have been reported [ 12 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b12#b12​)]. The tiny number of patients studied renders appraisal of the value of anti-CA II problematic. Anti-CA II has been demonstrated in autoimmune diseases such as systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS), and other immune-mediated diseases [ 13 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b13#b13​) (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b14#b14​)–15 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b15#b15​)]. Sjögren's syndrome itself may be associated with PBC [ 16 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b16#b16​)], and it has been speculated that in both diseases anti-CA II production is induced by exposure of the enzyme on the cell surface of injured duct epithelia [ 5 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b5#b5​), 8 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b8#b8​), 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​)]. With the aim of establishing whether anti-CA II is part of the serological manifestations of PBC, and whether its presence is associated with peculiar features of the disease, we studied a large population of consecutive patients with PBC and different AMA status examined at our centre to determine the prevalence of anti-CA II reactivity. Prevalence was compared with that of patients with pSS, systemic sclerosis (SSc), SLE or autoimmune hepatitis and that of matched healthy subjects.    SUBJECTS AND METHODSStudy populationThe PBC group consisted of all 215 patients who attended our centre between June 1994 and June 1996. For the present study the diagnosis of PBC was based on all the following internationally accepted criteria: presence of cholestatic liver disease for at least 6 months, liver biopsy compatible with the diagnosis, a positive test for AMA, serum alkaline phosphatase levels at least 1.5 times the upper limit of normal values, absence of biliary obstruction as assessed by ultrasonography, computed tomography, or endoscopic cholangiography. The patients meeting all the above mentioned criteria but lacking AMA were considered as having AMA−PBC [ 9 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b9#b9​)]. In these patients the AMA−result by indirect immunofluorescence had to be confirmed by a second determination and by immunoblotting. In the group of AMA−patients, those showing a positive ANA or SMA immunoreactivity were classified as having autoimmune cholangitis [ 2 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b2#b2​), 3 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b3#b3​)]. One hundred and sixty-five patients of this group participated in a longitudinal study that compared the clinical course of AMA−and AMA+ PBC [ 9 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b9#b9​)]. They represent all the subjects in that series who had not undergone liver transplantation and had a follow-up examination and serum collection between June 1994 and June 1996. The additional 50 cases included in the present study are those patients who were first visited during the above mentioned period. The following laboratory variables were considered: serum concentrations of alkaline phosphatase, alanine aminotransferase, total bilirubin, albumin, total and HDL cholesterol, triglycerides, immunoglobulins and prothrombin time; AMA; ANA and SMA, by indirect immunofluorescence; hepatitis B surface antigen and antibody to hepatitis B core antigen; antibody to hepatitis C virus (HCV). Antibodies to HCV were tested in all sera by third generation enzymatic immunoassay (Ortho, Raritan, NJ). Sera for anti-CA II testing were obtained from all PBC patients at the time of their enrolment into the study and stored at − 20°C until analysed. Patients positive for antibody to HCV represented 10% of the PBC series. A separate analysis including only PBC patients testing negative for antibody to HCV was also performed. Histological findings were classified according to Ludwig et al. [ 17 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b17#b17​)]. We also investigated the presence of symptoms, i.e. pruritus, jaundice, hepatic encephalopathy, variceal bleeding, or ascites; hepatocellular carcinoma; and associated autoimmune conditions, including Sjögren's syndrome (SS). Diagnosis of associated SS was re-evaluated on the basis of the presence of sicca symptoms, confirmed by Schirmer's tear test, and of serum autoantibodies to SS-A/Ro or SS-B/La proteins [ 18 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b18#b18​)]. Diagnosis of associated SSc was defined by the criteria of LeRoy and colleagues [ 19 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b19#b19​)]. The duration of PBC was calculated as the time interval between the date of earliest suspected evidence of liver disease and the date of examination at our centre. Sera for anti-CA II testing were obtained from the following control groups: 13 patients with autoimmune hepatitis, 25 patients with pSS, 12 patients with SSc, 19 patients with SLE, and 73 healthy subjects. The patients with autoimmune hepatitis had received a definite diagnosis according to the criteria of the International Autoimmune Hepatitis Group [ 20 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b20#b20​)], and were examined during the same period as the PBC patients. Ten of them had type 1 autoimmune hepatitis, while the remaining three had type 2 autoimmune hepatitis. Diagnosis of pSS, SSc, and SLE had been made according to internationally accepted criteria [ 18 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b18#b18​), 19 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b19#b19​), 21 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b21#b21​)]. The 73 healthy subjects were blood donors in the hospital where the study was carried out. The healthy subjects were matched with the PBC patients by gender and age class (≤ 50 years versus > 50 years). A detailed gynaecological history was collected from all female subjects, with special attention to endometriosis.The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and all patients gave consent after being informed of the nature and requirements of the study.Western immunoblotting of anti-CA IIPurified human erythrocyte CA II was purchased from Sigma Chemical Co. (St Louis, MO) (mol. wt 28 215). Briefly, antigens were diluted, at a final concentration of 0.5 mg/ml, in SDS sample buffer with 5 mmol/l Tris–HCl, 0.5% SDS, 1 mmol/l DL-dithiothreitol, pH 7.2, as described by Gordon et al. [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​)]. Bromophenol blue (at concentration of 0.05%) and glycerol (15%) were added. Samples were denatured by boiling for 7 min and were then submitted (10 μg/lane) to a 1.5-mm SDS–PAGE (12%) [ 22 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b22#b22​)]. Prestained molecular weight standards (mol. wt from 19 400 to 105 000; BioRad, Richmond, CA) were treated as above and were run on each gel. The proteins in the gel were then transblotted onto a nitrocellulose sheet (pore size 0.45 mm; Schleicher & Schuell, Keene, NH) in a Semi-Dry transfer system (BioRad) at a constant current of 2.4 mA/cm2 for 1 h. The immobilized CA II was stained in Ponceau red (Sigma) for a specific check of the transfer of proteins onto nitrocellulose, and then the nitrocellulose membrane was cut into 4-mm strips. To block non-specific binding, individual lanes of nitrocellulose carrying the antigens were incubated in Tris-buffered saline (TBS) containing 0.01 mol/l Tris–HCl pH 8.0, 0.15 mol/l NaCl and 5% milk, for 1 h at room temperature with gentle agitation. All strips were washed three times for 10 min each with TBS, and then incubated with serum samples diluted 1:40 and 1:100 in TBS and 5% milk for 1 h at room temperature. After three washes of 10 min each with TBS, nitrocellulose was incubated with rabbit peroxidase-linked antibodies against human total immunoglobulins (Dako, Glostrup, Denmark) diluted 1:1000 in TBS and 5% milk for 1 h at room temperature. Isotypes were detected in all sera testing positive for human total immunoglobulins to CA II, using specific rabbit peroxidase-coupled antisera (Dako) diluted 1:1000 (anti-IgG, anti-IgA) or 1:2000 (anti-IgM). The peroxidase was developed with 0.05% 4-chloro-1-naphthol (Sigma) in TBS containing 20% methanol and 0.05% H2O2 for 10 min at room temperature. All sera were tested in duplicate. As a positive control in each immunoblotting run a serum sample which resulted repeatedly positive was used. Sera anti-CA II+ at serum dilution of 1:100 were re-tested at increasing serum dilutions of 1:1000, 1:2500, 1:5000, 1:7500 and 1:10 000. Immunoreactivity to human CA II isoenzyme of three representative sera is shown in Fig. 1 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "f1#f1​).  Fig. 1. Immunoblot analysis of serum total immunoglobulin immunoreactivity to human antibody to carbonic anhydrase (CA II) isozyme. Antigen was separated by 12% SDS–PAGE and blotted onto nitrocellulose strips. Strips were incubated with increasing serum dilutions of sera of three anti-CA II+ patients with PBC (BC, CN and FE): lane 1, titre 1:40; lane 2, titre 1:100; lane 3, titre 1:1000; lane 4, titre 1:2500; lane 5, titre 1:5000; lane 6, titre 1:7500; lane 7, titre 1:1 0 000. Molecular mass markers (ovalbumin, 49 kD; carbonic anhydrase, 33 kD; soybean trypsin inhibitor, 29 kD) are indicated along the right margin of the figure.To choose the appropriate dilutions of the test serum, four sera testing negative for anti-CA II and four testing positive were assayed at increasing dilutions, i.e. 1:20, 1:40, 1:100, 1:250, 1:500. After titres of 1:40 and 1:100 were chosen, we tested the same eight serum samples with different dilutions of the enzymatically labelled antibodies against human total immunoglobulins, i.e. 1:500, 1:1000, 1:2000, and 1:5000. Because of the contrasting results obtained by others [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​), 12 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b12#b12​)], we performed several experiments (i) to evaluate if variations in methodological approaches may influence the results, and (ii) to choose the best technical conditions for detection of serum anti-CA II. No different results were found when we tested in parallel 10 sera testing negative for anti-CA II and 10 testing positive using different blocking procedures (TBS and 5% milk for 1 h at room temperature with gentle agitation versus TBS and 4% gelatin for 90 min in a shaking water bath at 37°C), and revealing antibodies to human immunoglobulins (non-biotinylated rabbit versus biotinylated goat). AMA evaluationsAMA were sought in each serum sample by indirect immunofluorescence on rat liver, kidney and stomach sections (The Binding Site, Birmingham, UK). Patients with at least two negative tests were considered to be AMA−. Negativity had to be confirmed by immunoblotting analysis of the PBC-specific serum autoantibody against the M2 component of the mitochondrial inner membrane. Sixteen of the 26 AMA−PBC patients had previously been classified as being negative by immunoblotting analysis [ 9 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b9#b9​)]. In the other 10 patients immunoblotting analysis was performed according to the same method used for testing anti-CA II with some modifications. Briefly, purified porcine pyruvate dehydrogenase complex (mol. wt 72 000; no. P-7032) and porcine 2-oxo-glutarate dehydrogenase complex (mol. wt 45 000) were purchased from Sigma. Antigens (7.5 μg/lane) were submitted to SDS–PAGE (10%) [ 22 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b22#b22​)]. The proteins in the gel were transblotted onto a nitrocellulose sheet (Schleicher & Schuell) in a Semi-Dry transfer system (BioRad), and then nitrocellulose membranes were cut into 4-mm strips. Each strip was incubated with serum samples at a dilution of 1:100, and then with rabbit peroxidase-linked antibodies against human total immunoglobulins (Dako) diluted 1:1000. The peroxidase was developed with 0.05% 4-chloro-1-naphthol (Sigma) in TBS containing 20% methanol and 0.05% H2O2 for 10 min at room temperature. All sera were tested in duplicate. Statistical analysisThe Mann–Whitney test was used to compare continuous variables in the groups of anti-CA II+ and anti-CA II− patients, and the χ2 or Fisher's exact tests to compare categorical variables. Logistic regression was used to determine which variables best discriminated between the two groups of PBC patients within the framework of multivariate analysis. The following variables were studied on the basis of their recognized association with severity of disease and prognosis or their immunological relevance: age, gender, serum bilirubin levels, ascites, SS, AMA positivity. Only the variables which were associated (P < 0.10) with anti-CA II status at univariate analysis were included in the logistic regression model. The goodness of fit for the estimated model was checked by the Pearson and by the Hosmer–Lemeshow tests, using a significance level of 0.10. Statistical comparisons were performed using Stata Statistical Software (Stata Corp., College Station, TX). Standard deviations or 95% confidence intervals were used as measures of variability. All analyses were two-sided, and, with the above mentioned exceptions, differences with P < 0.05 were considered statistically significant. RESULTSThe prevalence of anti-CA II reactivity in the PBC and control groups is reported in Table 1 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "t1#t1​). The proportion of PBC patients who tested positive for anti-CA II was similar in the two groups defined by AMA status. Twenty-three out of 26 (88%) AMA−PBC patients had autoimmune cholangitis, i.e. AMA−PBC and a positive test for ANA or SMA. When only this subgroup was considered, prevalence of anti-CA II was 9% at serum dilution of 1:100 and 30% at serum dilution of 1:40. The higher prevalence of women in the groups of patients with PBC, pSS, SSc, SLE, and autoimmune hepatitis reflects the unequal gender distribution in these diseases, while the similarity of the age and gender distribution of subjects in the PBC and the healthy group was expected as a result of the matching procedures. The two patients with autoimmune hepatitis who were anti-CA II+had type 1 hepatitis. Table 1. Antibody to carbonic anhydrase (anti-CA II) positivity in the study groups The clinical, histological, and laboratory characteristics of the PBC patients were compared according to anti-CA II status. The 59 patients who tested positive at serum dilution of 1:40 or higher had ascites more frequently (24% versus 12%, P = 0.032), SS more frequently (19% versus 6%, P = 0.010), and were less frequently male (3% versus 12%, P = 0.070). From Table 1 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "t1#t1​) it can be seen that at serum dilution of 1:100 the anti-CA II test better discriminated the patients with PBC, pSS, SSc or SLE from normal subjects and patients with autoimmune hepatitis. This level of immunoreactivity was therefore used for a more detailed evaluation of PBC patients ( Table 2 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "t2#t2​)). The 17 patients who tested positive for anti-CA II at this titre were all women. Ascites retained a significant association, and lower IgM levels were observed in the anti-CA II+ patients ( Table 3 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "t3#t3​)). A difference between anti-CA II+ and anti-CA II− patients with PBC was found in the frequency of sicca syndrome (88% versus 61%, P = 0.034). Associated SS was also more frequent in anti-CA II+ PBC patients compared with the anti-CA II−patients (24% versus 9%, P = 0.069). Table 2. Characteristics of the 17 PBC patients with high-titre antibody to carbonic anhydrase (anti-CA II) positivity Table 3. Clinical, biochemical and serological characteristics of patients with PBC according to antibody to carbonic anhydrase (anti-CA II) status Isotype study of sera from the 17 patients positive for anti-CA II at serum dilution of 1:100 showed a high frequency of IgG-anti-CA II (82% positive). The three patients without IgG-anti-CA II tested IgM-anti-CA II+. Overall, IgM-anti-CA II was detected in 41% of the patients. A low frequency of IgA-anti-CA II (11% positive) was also noted. Among the 32 patients with PBC and ascites, the 14 who tested positive for anti-CA II at a serum dilution of 1:40 or higher had a mean age of 61 ± 12 years compared with 66 ± 8 years in their 18 negative counterparts. The mean age was 58 ± 13 years in the six subjects who were positive at titres of 1:100 or higher and 65 ± 9 years in the 26 patients who tested negative at that titre.Logistic regression was performed considering age, gender, serum bilirubin levels, ascites, associated SS and AMA positivity as the study variables for the preliminary univariate analysis. Ascites (odds ratio 7.1; 95% confidence interval, 1.7–29.4; P = 0.006) and associated SS (5.1; 1.3–20.3; P = 0.022) were significantly associated with a positive test for anti-CA II at a serum dilution of 1:100 in the final logistic regression model. When only the 193 PBC patients testing negative for antibody to HCV were considered, prevalence of anti-CA II was 7% in the 170 AMA+ subjects, 2% in the 23 AMA−patients, and 10% in the 20 subjects with autoimmune cholangitis. Separate analysis of their data did not show any relevant difference compared with that performed in the overall PBC population. DISCUSSIONData from this cross-sectional study do not support the notion that anti-CA II is a distinctive feature of AMA−PBC, as CA II reactivity was not related to AMA status. This contrasts with the results obtained by Gordon et al. [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​)] in six patients with AMA−PBC and in 12 patients with AMA+ PBC, compared with a group of eight healthy subjects. These authors concluded that anti-CA II confers a unique pattern of immunoreactivity on patients lacking AMA. The most likely explanation for such divergent conclusions lies in the different sample size and patient selection criteria in the two studies. The present series consisted of 26 AMA−and 189 AMA+consecutive patients with PBC, who were matched with 73 healthy subjects. The large number and the modality of patient enrolment enabled us to obtain a reasonable estimate of the distribution of anti-CA II in PBC and also to limit selection biases. We devised a Western immunoblot technique similar to that used by Gordon et al. [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​)] to reveal specific binding to epitopes of the denatured form of CA II isozyme. Since we have obtained similar results from several comparative experiments adopting different methodological approaches, it seems that the reported discrepancies [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​), 12 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b12#b12​)] are not due to technical reasons. In our study the serum dilution of 1:40 was characterized by poor specificity, as recently noted by others [ 12 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b12#b12​)]. To assess specificity, sera were tested at different dilution levels up to extinction. By this procedure we demonstrated that in most patients showing CA II reactivity at a titre of 1:100 the antibody remained detectable at higher serum dilutions, whereas the 1:100 level of immunoreactivity discriminated the patients with PBC or pSS from normal subjects and patients with autoimmune hepatitis. Nevertheless, at these dilutions also we failed to observe a higher prevalence of anti-CA II in AMA−PBC or even in the subgroup of patients with autoimmune cholangitis. Therefore, we can confidently rule out that anti-CA II is a distinctive feature of AMA−PBC. Rather, using an appropriate serum dilution, we showed that CA II should be included in the list of autoantigens detectable in PBC. The high frequency of IgG-anti-CA II found among the 17 positive sera indicates that the data we obtained using an anti-human immunoglobulin antiserum directed to all immunoglobulin classes are comparable to those obtained by others [ 11 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b11#b11​), 12 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b12#b12​)] using an antiserum to the IgG isotype. The prevalence of anti-CA II in the patients with pSS was similar to that found in patients with PBC and associated SS. This is interesting in view of the report of high CA II concentrations both in submandibular and parotid glands and in biliary epithelia of normal individuals [ 23 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b23#b23​)]. Moreover, an experimental autoimmune sialoadenitis was induced in mice by intradermal immunization with human CA II [ 24 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b24#b24​)], and development of immune-mediated cholangitis with production of anti-CA II has been demonstrated in adult rats after the injection of highly purified cholangiocytes [ 25 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b25#b25​)]. A common immunopathogenic process, possibly induced by irregular distribution or expression of CA II in biliary and salivary duct tissues, may be hypothesized in patients with sialoadenitis and cholangitis, leading to the development of a 'dry gland' syndrome [ 5 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b5#b5​), 15 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b15#b15​), 26 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b26#b26​)]. The association between anti-CA II and ascites in PBC was unexpected. There is no evidence that CA II reactivity reflects more advanced disease, as the 17 positive patients were similar to their 198 negative counterparts in terms of serum bilirubin levels, presence of cirrhosis, and frequency of its major complications other than ascites. On the other hand, the patients with ascites and positive anti-CA II tended to be younger and, interestingly, anti-CA II positivity at high titre was observed in a patient who developed ascites without clinical or histological evidence of cirrhosis. The relation between anti-CA II and ascites draws attention to the important role of CA II in the regulation of fluid homeostasis. Carbonic anhydrases are a family of enzymes which catalyse the interconversion of carbon dioxide and bicarbonate and have a central role in physiological processes participating in the control of ion, fluid, and acid base balance in various tissues and organs [ 27 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b27#b27​)]. However, besides a report on the inhibitory effect of human anti-CA II on CA II enzymatic activity in vitro [ 14 (​http:​/​​/​www3.interscience.wiley.com​/​cgi-bin​/​fulltext​/​119104340​/​main.html,ftx_abs" \l "b14#b14​)], little is known about the physiopathologic consequences of deregulation of CA II or about the pathogenic role of its antibody. In conclusion, our results rule out a diagnostic role of anti-CA II in AMA−PBC and demonstrate that, in a subset of patients with PBC, disease-specific reactivity to CA II is detectable using an appropriate serum dilution. Anti-CA II is more prevalent in patients with PBC who are affected by SS and in those who present ascites, a finding which needs to be investigated in appropriate studies.       References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